• 1
    Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis – systemic review and up-to-date meta-analysis. Stroke 2004;35:29019.
  • 2
    Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 2003;91(suppl):23B9B.
  • 3
    Amarenco P, Bogousslavsky J, Callahan A III et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: high-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:54959.
  • 4
    Chan DK, O'Rourke F, Shen Q, Mak JC, Hung WT. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand 2011;124:18895.
  • 5
    Stroke Council, American Heart Association, American Stroke Association. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004;35:1023.
  • 6
    Mascitelli L, Pezzetta F. Concerns about efficacy and safety of statins in the prevention of stroke. Intern Med J 2009;39:20910.
  • 7
    Mascitelli L, Pezzetta F, Goldstein MR. Hemorrhagic stroke in the SPARCL study. Stroke 2008;39:e180; author reply e181.
  • 8
    Squizzato A, Dentali F, Romualdi E, Ageno W. Statins and secondary prevention of ischemic and hemorrhagic stroke. Stroke 2008;39:e113; author reply e114.
  • 9
    Mascitelli L, Pezzetta F, Goldstein MR. Low cholesterol, statin therapy, and intracerebral haemorrhage. Hong Kong Med J 2009;15:403.
  • 10
    Hu HH, Sheng WY, Chu FL, Lan CF, Chiang BN. Incidence of stroke in Taiwan. Stroke 1992;23:123741.
  • 11
    Tanaka H, Ueda Y, Hayashi M et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982;13:6273.
  • 12
    Lakhan SE, Baqchi S, Hofer M. Statins and clinical outcome of acute ischemic stroke: a systemic review. Int Arch Med 2010;3:22.
  • 13
    Gomis M, Ois A, Rodriquez-Campello A et al. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol 2010;17:4438.
  • 14
    Meier N, Nedeltchev K, Brekenfeld C et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 2009;40:172937.
  • 15
    Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007;68:73742.
  • 16
    Kent DM. Stroke-an equal opportunity for the initiation of statin therapy. N Engl J Med 2006;355:6135.
  • 17
    Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:23642.
  • 18
    Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke 2004;35:19415.
  • 19
    Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298300.
  • 20
    Montaner J, Chacon P, Krupinski J et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:8290.
  • 21
    Chen J, Zhang ZG, Li Y et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:74351.
  • 22
    Hankey GJ. Impact of treatment of people with transient ischaemic attack on stroke incidence and public health. Cerebrovasc Dis 1996;6(suppl 1):2633.
  • 23
    Johnson SC, Fayad PB, Gorelick PB et al. Prevalence and knowledge of transient ischemic attack among US adults. Neurology 2003;60:142934.
  • 24
    Kleindorfer D, Panagos P, Pancooli A et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005;36:7203.
  • 25
    Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in “low-risk” patients with a non-recent transient ischemic attack. J Neurol Neurosurg Psychiatry 2003;74:57780.
  • 26
    Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins? Atherosclerosis 2010;213:820.
  • 27
    Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:75767.
  • 28
    Vergouwen MD, De Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008;39:497502.
  • 29
    Kim BJ, Lee SH, Ryu WS, Kang BS, Kim CK, Yoon BW. Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism. Stroke 2009;40:162732.
  • 30
    Paciaroni M, Agnelli G, Corea F, Ageno W, Caso V, Silvestrelli G. Low levels of low-density lipoprotein cholesterol increase hemorrhagic transformation but not parenchymal hematoma in large artery atherothrombosis. Stroke 2009;40:e544; author reply e545.
  • 31
    Alvarez-Sabin J, Huertas R, Quintana M et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007;38:10768.
  • 32
    Montaner J. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Stroke 2008;39:e6.